Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study
Summary
The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia.
Timeline
- Start
- 2005-08
- Primary completion
- 2008-01
- Completion
- 2008-01
Outcome
Missed primary endpoint
registry analysis (superiority or other test); L-830982 vs Placebo; p = 0.16; ANOVA NCT00129441 ↗
registry analysis (superiority or other test); L-830982 vs Placebo; p = 0.162; ANOVA NCT00129441 ↗
registry analysis (superiority or other test); L-830982 vs Placebo; p = 0.12; ANOVA NCT00129441 ↗
registry analysis (superiority or other test); L-830982 vs Placebo; p = 0.05; ANOVA NCT00129441 ↗
registry analysis (superiority or other test); L-830982 vs Placebo; p = 0.249; ANOVA NCT00129441 ↗
Publications
- Background Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005 Apr;6(4):312-24. doi: 10.1038/nrn1648.
- Background Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl). 2004 Jun;174(1):143-50. doi: 10.1007/s00213-003-1673-x. Epub 2003 Dec 9.
- Results Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry. 2008 Dec;165(12):1585-93. doi: 10.1176/appi.ajp.2008.08030395. Epub 2008 Oct 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-830982 | Small molecule | 8 mg | — |